CRISPR/Cas9-mediated knockout of clinically relevant alloantigenes in human primary T cells
Open Access
- 29 January 2021
- journal article
- research article
- Published by Springer Nature in BMC Biotechnology
- Vol. 21 (1) , 1-10
Abstract
Background: The ability of CRISPR/Cas9 to mutate any desired genomic locus is being increasingly explored in the emerging area of cancer immunotherapy. In this respect, current efforts are mostly focused on the use of autologous (i.e. patient-derived) T cells. The autologous approach, however, has drawbacks in terms of manufacturing time, cost, feasibility and scalability that can affect therapeutic outcome or wider clinical application. The use of allogeneic T cells from healthy donors may overcome these limitations. For this strategy to work, the endogenous T cell receptor (TCR) needs to be knocked out in order to reduce off-tumor, graft-versus-host-disease (GvHD). Furthermore, CD52 may be knocked out in the donor T cells, since this leaves them resistant to the commonly used anti-CD52 monoclonal antibody lymphodepletion regimen aiming to suppress rejection of the infused T cells by the recipient. Despite the great prospect, genetic manipulation of human T cells remains challenging, in particular how to deliver the engineering reagents: virus-mediated delivery entails the inherent risk of altering cancer gene expression by the genomically integrated CRISPR/Cas9. This is avoided by delivery of CRISPR/Cas9 as ribonucleoproteins, which, however, are fragile and technically demanding to produce. Electroporation of CRISPR/Cas9 expression plasmids would bypass the above issues, as this approach is simple, the reagents are robust and easily produced and delivery is transient.Results: Here, we tested knockout of either TCR or CD52 in human primary T cells, using electroporation of CRISPR/Cas9 plasmids. After validating the CRISPR/Cas9 constructs in human 293 T cells by Tracking of Indels by Decomposition (TIDE) and Indel Detection by Amplicon Analysis (IDAA) on-target genomic analysis, we evaluated their efficacy in primary T cells. Four days after electroporation with the constructs, genomic analysis revealed a knockout rate of 12–14% for the two genes, which translated into 7–8% of cells showing complete loss of surface expression of TCR and CD52 proteins, as determined by flow cytometry analysis.Conclusion: Our results demonstrate that genomic knockout by electroporation of plasmids encoding CRISPR/Cas9 is technically feasible in human primary T cells, albeit at low efficiency.Keywords
Funding Information
- University of Isfahan (8178)
This publication has 46 references indexed in Scilit:
- Genome-wide Specificity of Highly Efficient TALENs and CRISPR/Cas9 for T Cell Receptor ModificationMolecular Therapy - Methods & Clinical Development, 2017
- Genome editing using FACS enrichment of nuclease-expressing cells and indel detection by amplicon analysisNature Protocols, 2017
- A versatile system for rapid multiplex genome-edited CAR T cell generationOncotarget, 2017
- Evaluation of TCR Gene Editing Achieved by TALENs, CRISPR/Cas9, and megaTAL NucleasesMolecular Therapy, 2016
- Easy quantitative assessment of genome editing by sequence trace decompositionNucleic Acids Research, 2014
- megaTALs: a rare-cleaving nuclease architecture for therapeutic genome engineeringNucleic Acids Research, 2013
- Modernizing the Nonhomologous End-Joining Repertoire: Alternative and Classical NHEJ Share the StageAnnual Review of Genetics, 2013
- ZFN, TALEN, and CRISPR/Cas-based methods for genome engineeringTrends in Biotechnology, 2013
- Meganucleases and Other Tools for Targeted Genome Engineering: Perspectives and Challenges for Gene TherapyCurrent Gene Therapy, 2011
- Assembly, intracellular processing, and expression at the cell surface of the human alpha beta T cell receptor/CD3 complex. Function of the CD3-zeta chain.The Journal of Immunology, 1989